Invion Limited, formerly CBio Limited, is an Australia-based company. The Company is engaged in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the Company�s Cpn10 technology. The Company operates as a research and development company in the pharmaceutical industry. The Company has completed the Phase I studies with both intravenous and subcutaneous administration, and three intravenous dosing Phase II clinical trials in rheumatoid arthritis (RA), psoriasis and multiple sclerosis. In August 2012, the Company announced the merger with the United States-based Inverseon Inc. was completed to create Invion Limited.